InMed-Mentari Merger Amended: PIPE Option Added, Tax-Free Status Confirmed
INM has more than doubled off its 52-week low of $0.575.
Summary
InMed amended its merger agreement with Mentari Therapeutics, adding a PIPE option for pre-closing financing and confirming the deal will be tax-free. The amendment also clarifies the closing sequence, including a name change, redomestication to Nevada, and a Nasdaq reverse split. This follows the original all-stock merger announcement in May and the recent S-4 filing, signaling progress toward closing. The PIPE option could strengthen Mentari's balance sheet before the merger, potentially improving the combined entity's cash position. The tax-free reorganization status removes a key uncertainty for shareholders.
At the time of this announcement, INM was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $0.58 to $3.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.